Effects of dydrogesterone and of its stable metabolite, 20-α-dihydrodydrogesterone, on nitric oxide synthesis in human endothelial cells

Fertility and Sterility

Volumn 86, Issue 4 SUPPL., 2006, Pages 1235-1242

  Simoncini, Tommaso ^a   Caruso, Antonella ^a   Giretti, Maria Silvia ^a   Scorticati, Camila ^a   Fu, Xiao Dong ^a   Garibaldi, Silvia ^a   Baldacci, Chiara ^a   Mannella, Paolo ^a   Fornari, Letizia ^a   Genazzani, Andrea R ^a  

^a Division of Obstetrics and Gynecology   (Italy)

Author keywords

20 dihydrodydrogesterone; Cardiovascular disease; dydrogesterone; endothelial cells; nitric oxide; progestins

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 20ALPHA DIHYDROPROGESTERONE; DRUG METABOLITE; DYDROGESTERONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE; PROGESTERONE; PROTEIN KINASE B;

ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DYDROGESTERONE; ENDOTHELIAL CELLS; ENZYME ACTIVATION; ESTRADIOL; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MITOGEN-ACTIVATED PROTEIN KINASES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PROGESTERONE; PROGESTINS; TRANSCRIPTION, GENETIC;

EID: 33748890173     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.05.018     Document Type: Article

References (31)

1. The Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
2. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
3. Mendelsohn M.E., and Karas R.H. Molecular and cellular basis of cardiovascular gender differences. Science 308 (2005) 1583-1587
4. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 8 Suppl 1 (2005) 3-63
5. van Amsterdam P.H., Overmars H., Scherpenisse P.M., and de Bree H. Dydrogesterone: metabolism in man. Eur J Drug Metab Pharmacokinet 5 (1980) 173-184
6. Nieto J.J., Cogswell D., Jesinger D., and Hardiman P. Lipid effects of hormone replacement therapy with sequential transdermal 17-beta-estradiol and oral dydrogesterone. Obstet Gynecol 95 (2000) 111-114
7. Campagnoli C., Colombo P., De Aloysio D., Gambacciani M., Grazioli I., Nappi C., et al. Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate. Maturitas 41 (2002) 299-311
8. Mijatovic V., Kenemans P., Netelenbos J.C., Peters-Muller E.R., van Kamp G.J., Voetberg G.A., et al. Oral 17 beta-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women. J Clin Endocrinol Metab 82 (1997) 3543-3547
9. Mijatovic V., Kenemans P., Jakobs C., van Baal W.M., Peters-Muller E.R., and van der Mooren M.J. A randomized controlled study of the effects of 17beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women. Obstet Gynecol 91 (1998) 432-436
10. Godsland I.F., Manassiev N.A., Felton C.V., Proudler A.J., Crook D., Whitehead M.I., et al. Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women. Clin Endocrinol (Oxf) 60 (2004) 541-549
11. Gaspard U.J., Wery O.J., Scheen A.J., Jaminet C., and Lefebvre P.J. Long-term effects of oral estradiol and dydrogesterone on carbohydrate metabolism in postmenopausal women. Climacteric 2 (1999) 93-100
12. de Kraker A.T., Kenemans P., Smolders R.G., Kroeks M.V., and van der Mooren M.J. The effects of 17 beta-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a). Maturitas 49 (2004) 253-263
13. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
14. Simoncini T., Mannella P., Fornari L., Caruso A., Willis M.Y., Garibaldi S., et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 145 (2004) 5745-5756
15. Simoncini T., Apa R., Reis F.M., Miceli F., Stomati M., Driul L., et al. Human umbilical vein endothelial cells: a new source and potential target for corticotropin-releasing factor. J Clin Endocrinol Metab 84 (1999) 2802-2806
16. Knowles R.G., and Salter M. Measurement of NOS activity by conversion of radiolabeled arginine to citrulline using ion-exchange separation. In: Titheradge M.A. (Ed). Nitric oxide protocols. Vol. 100 (1998), Humana Press, Totowa, NJ 67-73
17. Simoncini T., and Genazzani A.R. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab 85 (2000) 2966-2969
18. Simoncini T., Hafezi-Moghadam A., Brazil D.P., Ley K., Chin W.W., and Liao J.K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407 (2000) 538-541
19. Simoncini T., and Genazzani A.R. Non-genomic actions of sex steroid hormones. Eur J Endocrinol 148 (2003) 281-292
20. Simoncini T., Rabkin E., and Liao J.K. Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells. Arterioscler Thromb Vasc Biol 23 (2003) 198-203
21. Simoncini T., Maffei S., Basta G., Barsacchi G., Genazzani A.R., Liao J.K., et al. Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. Circ Res 87 (2000) 19-25
22. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 47 (2004) 277-283
23. Miyagawa K., Rosch J., Stanczyk F., and Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 3 (1997) 324-327
24. Register T.C., Adams M.R., Golden D.L., and Clarkson T.B. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol 18 (1998) 1164-1171
25. Adams M.R., Kaplan J.R., Manuck S.B., Koritnik D.R., Parks J.S., Wolfe M.S., et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 10 (1990) 1051-1057
26. Rosano G.M., Webb C.M., Chierchia S., Morgani G.L., Gabraele M., Sarrel P.M., et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol 36 (2000) 2154-2159
27. Nilsen J., and Brinton R.D. Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology 143 (2002) 205-212
28. Nilsen J., and Brinton R.D. Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc Natl Acad Sci U S A 100 (2003) 10506-10511
29. Hafezi-Moghadam A., Simoncini T., Yang E., Limbourg F.P., Plumier J.C., Rebsamen M.C., et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 8 (2002) 473-479
30. Simoncini T., Mannella P., Fornari L., Varone G., Caruso A., and Genazzani A.R. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology 144 (2003) 3449-3455
31. McDonnell D.P. The molecular determinants of estrogen receptor pharmacology. Maturitas 48 Suppl 1 (2004) S7-S12